Vancomycin Derivatives with Lipophilic Linkers for Antibacterial Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibacterial agents, such as glycopeptide antibiotics, face challenges with physiological stability and resistance from Gram-positive bacteria, leading to the need for new agents with improved stability and efficacy against bacterial infections.
Innovation Solution
Development of novel glycopeptide derivatives with specific linking groups and lipophilic elements that enhance stability and reduce proteolysis, while maintaining antimicrobial activity, including compounds of the formula X—W-L-V, where X is a lipophilic group, W is a basic amino acid or peptide, and L is a linking group, attached to a glycopeptide moiety that inhibits peptidoglycan biosynthesis in bacteria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glycopeptide antibiotics are used to treat bacterial infections, then antibacterial activity is achieved, but physiological stability deteriorates and resistance develops
Solution Approach 1:
The patent modifies the chemical structure of glycopeptide antibiotics by changing parameters such as adding lipophilic groups, modifying amino acid sequences, and altering sugar moieties. These parameter changes enhance physiological stability while preserving antibacterial activity against resistant strains including MRSA and VRE.
Solution Approach 2:
The invention creates composite structures by combining glycopeptide cores with additional functional elements such as lipophilic side chains, modified sugar residues, and peptide extensions. These composite molecules exhibit both improved stability in physiological conditions and maintained or enhanced antibacterial efficacy.
2Reliability
If existing glycopeptide derivatives are developed to combat resistant strains, then activity against resistant bacteria improves, but complexity of the compound structure increases
Solution Approach 1:
The patent applies local quality modifications by making specific targeted changes to particular regions of the glycopeptide molecule rather than comprehensive restructuring. Examples include modifying specific sugar moieties, adding functional groups at specific positions, or altering particular amino acid residues while keeping the core structure relatively simple and recognizable.
3Stability of the object's composition
If novel glycopeptide derivatives with enhanced stability are created, then physiological stability improves, but difficulty of synthesis increases
Solution Approach 1:
The patent employs segmentation by dividing the complex glycopeptide synthesis into separate modular stages: core glycopeptide assembly, subsequent attachment of lipophilic groups, and final modifications of sugar or peptide moieties. This segmented approach allows each stage to be optimized independently, improving overall manufacturability despite the complexity of the final stable compound.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new compounds demonstrate improved stability and antibacterial activity against resistant strains, including MRSA, with enhanced pharmacokinetic profiles and reduced potential for degradation, making them effective for treating bacterial infections.
Implementation Method 1
The D-Ala-D-Ala dipeptide forms complementary hydrogen bonds with the peptide backbone of vancomycin
Implementation Method 2
X is a lipophilic group attached to the N-terminus of W
Implementation Method 3
W is a basic amino acid or a basic peptide consisting of from 2 to 10 amino acids
Data Source
AI summary
The invention concerns agents with antibacterial activity, their production and use in the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure X—W-L-V, wherein X is hydrogen, acetyl or a lipophilic membrane-insertive element, W is a basic peptide or basic amino acid; L is a linking group and V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria.